Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

PURPOSE: Sorafenib is an inhibitor of VEGFR, PDGFR, and RAF kinases, amongst others. We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel +/− sora...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058354/
https://ncbi.nlm.nih.gov/pubmed/24714776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados